Biotech Archives - Page 778 of 795

1 minute read

Medigus’ Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries

July 18, 8:51 AM

Polyrizon Ltd, in which Medigus Ltd (NASDAQ:MDGS) owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal…

MDGS

2 minute read

Medigus Announces Polyrizon Signs Binding Collaboration Agreement With NurExone Biologic For Intranasal Administration Of Therapy For Spinal Cord Injuries, Polyrizon Is Entitled For Up to $3.35M Plus Future Royalties; Medigus Owns 37.03% Of Polyrizon

By Bill Haddad

July 18, 8:07 AM

Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd.

MDGS

4 minute read

Polyrizon Signed An Agreement With Nurexone For Intranasal Administration Of Therapy For Spinal Cord Injuries. BZ NOTE: Medigus Owns 37.03% Of Polyrizon

By Benzinga Newsdesk

July 18, 8:07 AM

Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries Polyrizon will be entitled for up to $3.35 million in addition to future

MDGS

2 minute read

Eledon Pharmaceuticals Announces The First Patient Dosed In Phase 1b Trial Evaluating Tegoprubart In Kidney Transplantation

By Benzinga Newsdesk

July 18, 8:01 AM

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell

ELDN

1 minute read

GSK Completes Spin Off Of Its Consumer Healthcare Business

By Vandana Singh

July 18, 7:41 AM

GSK plc (NYSE:GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. Reuters reported that shares in…

GSK

1 minute read

Eton Pharmaceuticals Announces FDA Approval Of ZONISADE

By Benzinga Newsdesk

July 18, 7:11 AM

Eton Pharmaceuticals, Inc. (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has

ETON

1 minute read

Eliem Announces Updated Development Plans And The Advancement Of ETX-155 For The Treatment Of Major Depressive Disorder

By Benzinga Newsdesk

July 18, 7:09 AM

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024

ELYM

3 minute read

UK’s National Institute for Health and Care Excellence Recommended Rhythm’s IMCIVREE (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

By Charles Gross

July 18, 6:11 AM

Rhythm Pharmaceuticals, Inc.

RYTM

1 minute read

Regulus Therapeutics Announces On July 12, Sanofi Notified Co. Of Its Decision To Terminate Phase 2 Clinical Study Of Lademirsen For Treatment Of Alport Syndrome

By Benzinga Newsdesk

July 15, 4:10 PM

https://www.sec.gov/ix?doc=/Archives/edgar/data/1505512/000119312522194935/d346170d8k.htm

RGLS

1 minute read

Embraer Shares See Volume, Co. Granted U.S. Patent Titled ‘VERTICAL TAKE-OFF AND LANDING (VTOL) AIRCRAFT WITH ROTOR CONFIGURATIONS TOLERANT TO ROTOR FAILURE’

By Michael Horton

July 15, 3:35 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11383830&OS=11383830&RS=11383830

ERJ